Early use of low dose tocilizumab in patients with COVID-19: A retrospective cohort study with a complete follow-up
Pneumonia with severe respiratory failure represents the principal cause of death in COVID-19, where hyper-inflammation plays an important role in lung damage. An effective treatment aiming at reducing the inflammation without preventing virus clearance is thus urgently needed. Tocilizumab, an anti-...
- Autores:
- Tipo de recurso:
- Article of journal
- Fecha de publicación:
- 2020
- Institución:
- Universidad de Bogotá Jorge Tadeo Lozano
- Repositorio:
- Expeditio: repositorio UTadeo
- Idioma:
- eng
- OAI Identifier:
- oai:expeditiorepositorio.utadeo.edu.co:20.500.12010/13493
- Acceso en línea:
- https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(20)30203-0/fulltext
http://hdl.handle.net/20.500.12010/13493
https://doi.org/10.1016/j.eclinm.2020.100459
- Palabra clave:
- tocilizumab
tocilizumab
anti-soluble IL-6 receptor
Síndrome respiratorio agudo grave
COVID-19
SARS-CoV-2
Coronavirus
- Rights
- License
- Acceso restringido